**Antonio Marchini**

Dr. Antonio Marchini is Head of the Laboratory of Oncolytic Virus Immuno Therapeutics (LOVIT), a binational research unit at the Luxembourg Institute of Health (LIH, Luxembourg) and German Cancer Research Center (DKFZ, Heidelberg, Germany). His Team focuses on the development of new anticancer strategies based on oncolytic autonomous parvoviruses (PVs). Major areas of research are: i) generation of innovative oncolytic vectors: retargeted PVs, chimeric vectors of adenovirus-PV genomes, PVs expressing sh/miRNAs; ii) design and assessment of novel combination therapies using PVs together with other anticancer agents such as apoptosis inducers, immune checkpoint blockade and/or epigenetic modulators of gene expression, iii) identification of H-1PV cellular modulators and predictive biomarkers of viral oncolysis. He earned his Ph.D degree at the University of Heidelberg in 2001, working on the identification of new cellular proteins interacting with human papillomavirus 16 E7 oncoprotein.
